中國再保險(01508.HK):楊長松董事任職資格獲銀保監會核准
格隆匯11月8日丨中國再保險(01508.HK)發佈公吿,公司於2022年11月3日收到中國銀保監會關於楊長松先生任職資格的批覆。根據該批覆,中國銀保監會核准楊長松先生擔任公司董事的任職資格。公司於2022年11月8日正式任命楊長松先生為非執行董事、董事會戰略與投資委員會委員、提名薪酬委員會委員及副主任委員,楊長松先生自該日起正式履職,任期至第四屆董事會任期屆滿為止,任期屆滿可獲重選連任。
此外,因工作調動,温寧先生提出辭任非執行董事、董事會戰略與投資委員會委員、提名薪酬委員會委員及副主任委員職務。該辭任自2022年11月8日温寧先生辭任信函送達董事會之日起生效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.